Last Updated: November 16, 2026

EPSOLAY Drug Patent Profile

« Back to Dashboard


When do Epsolay patents expire, and what generic alternatives are available?

Epsolay is a drug marketed by Mayne Pharma and is included in one NDA. There are fourteen patents protecting this drug.

The generic ingredient in EPSOLAY is benzoyl peroxide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the benzoyl peroxide profile page.

DrugPatentWatch® Generic Entry Outlook for Epsolay

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 3, 2028. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for EPSOLAY?
  • What are the global sales for EPSOLAY?
  • What is Average Wholesale Price for EPSOLAY?
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for EPSOLAY
Generic Entry Date for EPSOLAY*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:

CREAM;TOPICAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for EPSOLAY

EPSOLAY is protected by fourteen US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of EPSOLAY is ⤷  Start Trial.

This potential generic entry date is based on patent 12,350,382.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mayne Pharma EPSOLAY benzoyl peroxide CREAM;TOPICAL 214510-001 Apr 22, 2022 RX Yes Yes 10,945,987 ⤷  Start Trial ⤷  Start Trial
Mayne Pharma EPSOLAY benzoyl peroxide CREAM;TOPICAL 214510-001 Apr 22, 2022 RX Yes Yes 10,933,046 ⤷  Start Trial Y ⤷  Start Trial
Mayne Pharma EPSOLAY benzoyl peroxide CREAM;TOPICAL 214510-001 Apr 22, 2022 RX Yes Yes 12,257,348 ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for EPSOLAY

When does loss-of-exclusivity occur for EPSOLAY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 08211554
Estimated Expiration: ⤷  Start Trial

Brazil

Patent: 0808160
Estimated Expiration: ⤷  Start Trial

Canada

Patent: 77185
Patent: METHODE DE PREPARATION DE PARTICULES COMPRENANT UN ENROBAGE D'OXYDE METALLIQUE, ET PARTICULES ENROBEES D'OXYDE METALLIQUE (METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING)
Estimated Expiration: ⤷  Start Trial

Patent: 24842
Patent: METHODE DE PREPARATION DE PARTICULES COMPRENANT UN ENROBAGE D'OXYDE METALLIQUE, ET PARTICULES ENROBEES D'OXYDE METALLIQUE (METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING)
Estimated Expiration: ⤷  Start Trial

China

Patent: 1754677
Patent: Method for preparing particles comprising metal oxide coating and particles with metal oxide coating
Estimated Expiration: ⤷  Start Trial

Eurasian Patent Organization

Patent: 8275
Patent: СПОСОБ ПОЛУЧЕНИЯ ЧАСТИЦ, СОДЕРЖАЩИХ ПОКРЫТИЕ ИЗ ОКСИДА МЕТАЛЛА, И ЧАСТИЦЫ С ПОКРЫТИЕМ ИЗ ОКСИДА МЕТАЛЛА (METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING)
Estimated Expiration: ⤷  Start Trial

Patent: 0970725
Patent: СПОСОБ ПОЛУЧЕНИЯ ЧАСТИЦ, СОДЕРЖАЩИХ ПОКРЫТИЕ ИЗ ОКСИДА МЕТАЛЛА, И ЧАСТИЦЫ С ПОКРЫТИЕМ ИЗ ОКСИДА МЕТАЛЛА (METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING)
Estimated Expiration: ⤷  Start Trial

European Patent Office

Patent: 18208
Patent: MÉTHODE DE PRÉPARATION DE PARTICULES COMPRENANT UN ENROBAGE D'OXYDE MÉTALLIQUE (METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING)
Estimated Expiration: ⤷  Start Trial

Patent: 45776
Patent: Procédé de préparation de particules comprenant un revêtement d'oxyde métallique et particules à revêtement d'oxyde métallique (Method for preparing particles comprising metal oxide coating and particles with metal oxide coating)
Estimated Expiration: ⤷  Start Trial

Japan

Patent: 82723
Estimated Expiration: ⤷  Start Trial

Patent: 10517997
Estimated Expiration: ⤷  Start Trial

Mexico

Patent: 2876
Patent: METODO PARA PREPARAR PARTICULAS QUE COMPRENDEN RECUBRIMIENTO DE OXIDO DE METAL Y PARTICULAS CON RECUBRIMIENTO DE OXIDO DE METAL. (METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING.)
Estimated Expiration: ⤷  Start Trial

Patent: 09008256
Patent: METODO PARA PREPARAR PARTICULAS QUE COMPRENDEN RECUBRIMIENTO DE OXIDO DE METAL Y PARTICULAS CON RECUBRIMIENTO DE OXIDO DE METAL. (METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING.)
Estimated Expiration: ⤷  Start Trial

South Africa

Patent: 0905365
Patent: METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING
Estimated Expiration: ⤷  Start Trial

South Korea

Patent: 090121291
Patent: METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING
Estimated Expiration: ⤷  Start Trial

Spain

Patent: 63829
Estimated Expiration: ⤷  Start Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering EPSOLAY around the world.

Country Patent Number Title Estimated Expiration
Canada 3130362 PROCEDE PERMETTANT DE FOURNIR UN DEBUT D'ACTION PRECOCE DANS LE TRAITEMENT DE LA ROSACEE (METHOD FOR PROVIDING EARLY ONSET OF ACTION IN THE TREATMENT OF ROSACEA) ⤷  Start Trial
Canada 3130437 METHODE DE TRAITEMENT DE LA ROSACEE (METHOD FOR TREATMENT OF ROSACEA) ⤷  Start Trial
Canada 3130439 METHODE DE TRAITEMENT DE LA ROSACEE CHEZ DES PATIENTS AGES DE 65 ANS ET PLUS (METHOD FOR TREATMENT OF ROSACEA IN PATIENTS AGED 65 YEARS AND OLDER) ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for EPSOLAY

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1458369 CA 2008 00029 Denmark ⤷  Start Trial PRODUCT NAME: ADAPALEN, BENZOYLPEROXID
1458369 SPC/GB10/005 United Kingdom ⤷  Start Trial PRODUCT NAME: ADAPALENE AND BENZOYL PEROXIDE; REGISTERED: DK 40440 20071218; UK PL10590/0057 20091111
1458369 C01458369/01 Switzerland ⤷  Start Trial PRODUCT NAME: ADAPALENUM + BENZOYLIS PEROXIDUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 58460 19.05.2009
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.